Drug Trial Radar · NCT06257966
A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin
Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
600
Actual
Start
Jul 17, 2024
Primary completion
Oct 1, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- Beijing Dongfang Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to compare the efficacy and safety of two JY09 doses versus dulaglutide as add-on therapy to metformin in participants with type 2 diabetes mellitus (T2DM)
Conditions
- Type2 Diabetes Mellitus
Interventions
Exendin-4 Fc fusion protein injection(1.2mg)Drug
1.2mg, subcutaneous injection in the abdomen, biweekly, 54 weeks of treatment.
Exendin-4 Fc fusion protein injection(2.4mg)Drug
The first dose of 1.2 mg was administered subcutaneously in the abdomen, and after two weeks, the dose was adjusted to 2.4 mg, followed by a continuation of treatment for 52 weeks.
DulaglutideDrug
1.5 mg dulaglutide injection subcutaneously once a week for 54 weeks.
MetforminDrug
Metformin hydrochloride tablets, oral administration, 54 weeks of treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- HbA1cTime frame: Baseline, Week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.